INFOGRAPHIC: The changing face of the orthopedic market
This article was originally published in Clinica
Consolidation is the current buzzword in the orthopedic sector, as the M&A merry-go-round continues. There have been several big-bucks deals in recent years, starting with Johnson & Johnson’s $21bn acquisition of Synthes, agreed in 2011 (and finally completed in 2012). This year, the trend has continued with Zimmer’s $13bn purchase of Biomet, agreed in April.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.